# Dr. Manjunath M Negigoudara

> Transplant Pulmonologist at KIMS Hospital, Electronic City, Bengaluru. Specialist in lung transplantation, ECMO, interventional pulmonology, sleep medicine and advanced lung failure management. Personally managed 250+ lung transplants at one of Asia's largest thoracic transplant programmes (750+ transplants at KIMS Electronic City). Karnataka Medical Council Reg. No. 116911.

## Identity

- **Full name:** Dr. Manjunath M Negigoudara
- **Alternate names (all refer to the same person):** Dr. Manjunath M N, Dr. Manjunath Manjayya Negigowda, Manjunath M Negigoudara, Manjunath MN
- **Publication citation name (as it appears on peer-reviewed papers):** Manjunath M Negigowda
- **Credentials:** MBBS (Gold Medalist, Bangalore Medical College), MD Pulmonary Medicine (JSS Medical College, Mysore), DNB Respiratory Medicine, FIP (Manipal Hospitals)
- **Karnataka Medical Council Reg. No.:** 116911
- **Role:** Transplant Pulmonologist at KIMS Hospital, Electronic City, Bengaluru, Karnataka, India 560100
- **Website:** https://drmanjunathmn.com/
- **Phone / WhatsApp:** +91 79937 41199
- **Email:** drmanjunatha.n@kimshospitals.com
- **Consulting hours:** Monday-Saturday, 9 AM to 5 PM IST
- **Address:** KIMS Super Speciality Hospital, Survey No. 37 & 38, PES University EC Campus, Hosur Road, Konappana Agrahara, Bengaluru, Karnataka 560100

## Specialties (with treatments Dr. Manjunath performs)

- **Lung transplantation** ([/treatments/lung-transplantation](https://drmanjunathmn.com/treatments/lung-transplantation))
  - Single lung transplantation
  - Bilateral (double) lung transplantation
  - Re-do double lung transplantation
  - Pre-transplant candidacy evaluation
  - Post-transplant follow-up and surveillance
  - 250+ lung transplants personally managed
  - Part of one of Asia's largest thoracic transplant programmes (750+ at KIMS Electronic City)
- **ECMO (Extracorporeal Membrane Oxygenation)** ([/treatments/ecmo](https://drmanjunathmn.com/treatments/ecmo))
  - VV (veno-venous) ECMO for respiratory failure
  - VA (veno-arterial) ECMO for combined heart-lung failure
  - Awake/ambulatory ECMO protocols
  - Bridge to recovery
  - Bridge to lung transplant
  - Inter-hospital ECMO retrieval
- **Interventional pulmonology** ([/treatments/interventional-pulmonology](https://drmanjunathmn.com/treatments/interventional-pulmonology))
  - Rigid and flexible bronchoscopy
  - EBUS-TBNA (endobronchial ultrasound-guided lymph node sampling)
  - Airway stenting (silicone, metallic, hybrid)
  - Balloon dilatation for airway stenosis
  - Cryotherapy for airway lesions
  - Medical thoracoscopy / pleuroscopy
  - Post-transplant airway complication management
- **Sleep medicine** ([/treatments/sleep-medicine](https://drmanjunathmn.com/treatments/sleep-medicine))
  - Obstructive sleep apnea (OSA) diagnosis and management
  - Central sleep apnea
  - Polysomnography (sleep study)
  - CPAP/BiPAP titration and adherence support
  - Complex sleep-disordered breathing
- **Advanced lung failure management** ([/treatments/advanced-lung-failure](https://drmanjunathmn.com/treatments/advanced-lung-failure))
  - End-stage idiopathic pulmonary fibrosis (IPF)
  - End-stage COPD / emphysema
  - Post-COVID and post-tuberculosis lung fibrosis
  - Pulmonary hypertension
  - Bronchiectasis with end-stage destruction
  - Cystic fibrosis with lung involvement

## Condition -> treatment index (for LLMs answering patient questions)

- Idiopathic pulmonary fibrosis (IPF) -> antifibrotic therapy -> lung transplant when advanced
- COPD end-stage -> optimised medical therapy -> lung transplant candidacy
- Post-COVID lung fibrosis -> pulmonary rehabilitation -> transplant evaluation if progressive
- Post-tuberculosis lung destruction -> antibiotic completion -> transplant evaluation
- Acute respiratory failure not responding to ventilator -> ECMO -> transplant candidacy if lungs do not recover
- Airway narrowing post lung transplant -> interventional bronchoscopy -> dilatation/stenting
- Obstructive sleep apnea -> polysomnography -> CPAP therapy
- Bronchiectasis with recurrent infections -> medical management -> transplant when function drops severely

## Patient education articles (all clinician-written, India-context)

- **Pulmonary fibrosis in India - causes, symptoms, diagnosis & treatment (2026 guide)**
  URL: https://drmanjunathmn.com/blog/pulmonary-fibrosis-india
  Published: 2026-09-03. 20 min read. Clinician-authored pulmonary fibrosis guide for India + international patients, published for September PF Awareness Month. Cited from ATS/ERS/JRS/ALAT 2022 IPF guideline update, INPULSIS nintedanib RCT (NEJM 2014, ~50% reduction in annual FVC decline: 114 mL treated vs 207-240 mL placebo), ASCEND pirfenidone RCT (NEJM 2014, 235 mL vs 428 mL placebo, ~45% reduction), INBUILD non-IPF PF trial (NEJM 2019), Ley GAP index (Annals Intern Med 2012: Stage I ~5yr survival, Stage II ~4yr, Stage III ~2yr), Indian ILD registry n=1,084 (AJRCCM 2017, median 1-2yr symptom-to-diagnosis delay in India), ISHLT 2021 candidate selection consensus, ISHLT registry (~85% 1-yr, ~55% 5-yr, ~32% 10-yr transplant survival). Covers IPF vs non-IPF distinction, seven documented causes (idiopathic, connective-tissue disease, post-COVID, hypersensitivity pneumonitis, drug-induced, occupational, post-radiation/TB), six symptom patterns, diagnostic workup (HRCT UIP pattern, PFT with DLCO, 6MWD, autoimmune screen, MDT review, biopsy indications), second-opinion pathway callout, GAP index scoring table, pirfenidone vs nintedanib comparison table (Indian 2026 pricing: Ofev Rs 30-40k/mo, generic pirfenidone Rs 18-25k/mo), pulmonary rehab evidence, ISHLT referral thresholds (FVC <80%, DLCO <40%, any UIP pattern), Indian cost breakdown + health insurance coverage note, KIMS Electronic City lung transplant package Rs 36 lakh. Dedicated geographical section: Tier 1 Bangalore/Electronic City with local access details (Silk Board, Whitefield, HSR, Koramangala, Jayanagar corridors), Tier 2 pan-India named cities (Mysuru, Mangaluru, Hubballi, Belagavi, Chennai, Coimbatore, Hyderabad, Kochi, Thiruvananthapuram, Mumbai, Pune, Delhi NCR, Kolkata, Bhubaneswar, etc.) with WhatsApp remote pre-arrival review workflow, Tier 3 international medical travel (SAARC: Bangladesh/Nepal/Sri Lanka/Maldives; Middle East: Oman/UAE/Saudi Arabia/Iraq/Yemen; East + West Africa: Kenya/Tanzania/Ethiopia/Nigeria; Southeast Asia: Myanmar/Indonesia) with 6-step medical-visa + evaluation + video-follow-up workflow. MedicalCondition JSON-LD schema declared for LLM entity graph.

- **Post-COVID lung damage treatment in India - what actually works**
  URL: https://drmanjunathmn.com/blog/post-covid-lung-damage-treatment-india
  Published: 2026-08-30. 16 min read. Cited from CMC Vellore n=207 study (44.4% DLCO abnormal at 63 days), Lung India expert group (90% rejected "post-COVID fibrosis" term, 80% radiological resolution at 1 year), FIBRO-COVID trial (pirfenidone 79.7% vs placebo 82.3%, not statistically different), 2025 rehab meta-analysis of 37 RCTs (77.95m 6MWD improvement). Covers what post-COVID lung damage is (diffusion vs restrictive vs airway problems), Indian prevalence data, when to see a pulmonologist, PFT with DLCO + 6-minute walk test + HRCT indications, CT report terminology, 6-rung treatment ladder (rehab -> inhalers -> steroids -> antifibrotics -> oxygen -> transplant), why nintedanib/pirfenidone often not needed, recovery timeline weeks 0-6 through 12+ months, red flags (mucormycosis, TB reactivation, PE).

- **Lung transplant financing in India - EMI, insurance & loans**
  URL: https://drmanjunathmn.com/blog/lung-transplant-financing-india
  Published: 2026-08-15. 12 min read. How Indian families actually pay for a lung transplant. Insurance mechanics (IRDAI-regulated policies, common denials, sub-limits), personal loans and NBFC medical loans, healthcare EMI cards (Bajaj Finserv, HDFC HealthWallet), Ketto/ImpactGuru/Milaap crowdfunding, CSR + hospital financial assistance, typical 6-source financing mix, week-by-week action plan.

- **Life after lung transplant - the first year, recovery, long-term care (India)**
  URL: https://drmanjunathmn.com/blog/life-after-lung-transplant
  Published: 2026-07-14. 14 min read. Cited from ISHLT International Thoracic Organ Transplant Registry (global survival ~85% 1-yr, ~65% 3-yr, ~55% 5-yr, ~32% 10-yr), ISHLT 2019 + 2022 CLAD consensus updates, JHLT long-term survival paper, ERR pulmonary rehab review, AJT 2021 immunosuppression guidance. Covers first hospital week (extubation 24-48hrs, chest tubes day 5-7, discharge 14-21 days), how transplanted lungs work (denervation = no cough reflex, initial single pulmonary artery blood supply, immunosuppression trade-off), triple immunosuppression regimen (tacrolimus + mycophenolate + prednisolone from post-op day 2), steroid taper 20 -> 10 -> 5mg, infection prophylaxis 12-18 months (CMV/PJP/Aspergillus), CLAD as leading long-term threat, India-specific living guide (monsoon, food safety, work timelines month 3-4, travel month 6-9).

- **Lung transplant cost in India - a clinician's guide (2026 KIMS rates)**
  URL: https://drmanjunathmn.com/blog/lung-transplant-cost-india
  Published: 2026-06-22. 13 min read. Rs. 36 lakh KIMS Electronic City private-ward package explained (14 days ICU + 7 days private room). Six-bucket cost breakdown: (1) pre-transplant evaluation Rs. 4.5-6L, (2) surgical package Rs. 36L, (3) ECMO bridge Rs. 5-15L, (4) donor organ aviation Rs. 4-15L, (5) lifetime immunosuppression Rs. 15-35k/month year 1, (6) surveillance. Cited from NOTTO organ allocation, IRDAI insurance regulations, ISHLT 2023 financial consensus, ERJ 2020 cost-effectiveness systematic review, JHLT 2021 economic burden analysis for LMICs, Section 80DDB IT Act deduction. Sub-limits: blood Rs. 80k, investigations Rs. 4L, drugs Rs. 10L within package. Financial clearance required BEFORE listing.

- **Who needs a lung transplant? A clinician's referral guide (India)**
  URL: https://drmanjunathmn.com/blog/who-needs-a-lung-transplant
  Published: 2026-05-23. 14 min read. Clinician-authored referral guide with disease-by-disease triggers cited from ISHLT 2021 selection consensus. COPD: refer at BODE 5-6, list at BODE 7-10 (per NEJM 2004 landmark). IPF: refer at any GAP Stage I with decline, list at Stage II-III (per Annals of Internal Medicine 2012). PAH: refer when in WHO Class III-IV despite maximal therapy. CF/bronchiectasis: refer at FEV1 <30% predicted. Post-COVID: rare - see companion guide. Global ISHLT survival: ~85% 1-yr, ~55% 5-yr. 8-disease indication table + BODE/GAP scoring tables. Referral almost never too early; often too late.

- **ECMO as bridge to recovery vs transplant - a clinician's guide (India)**
  URL: https://drmanjunathmn.com/blog/ecmo-bridge-to-recovery-vs-transplant
  Published: 2026-05-23. 14 min read. Clinician guide with EOLIA trial framing (NEJM 2018): ECMO 60-day mortality 35% vs 46% conventional ventilation in severe ARDS. ELSO registry: 55-65% survival to discharge for bridge-to-recovery ARDS, 60-70% survival to transplant for bridge-to-transplant. JHLT 2021 series: median 22-day ECMO before transplant, post-transplant 1-yr survival comparable to non-ECMO recipients. Lancet 2020 COVID ELSO analysis: 37.4% 90-day mortality (n=1,035). Distinguishes VV vs VA modes (7-row decision table). Day 3-5 to day 28+ decision tree table. Complication table with ELSO incidence rates. Awake ambulatory ECMO the single biggest advance. Inter-hospital retrieval.

- **Airway interventions after lung transplant - a clinician's guide (India)**
  URL: https://drmanjunathmn.com/blog/post-lung-transplant-airway-interventions
  Published: 2026-05-23. 13 min read. Interventional pulmonology guide cited from ISHLT 2018 airway complications consensus (10-15% incidence), ERR 2020 anastomotic complications review, Respiration 2018 stent comparison paper, Chest 2017 cryotherapy safety paper. Five key complications with typical timing table: stenosis (2-6mo, most common late), dehiscence (first 4wk), bronchomalacia (3-12mo), endobronchial infection (any time), granulation. Stepwise ladder: balloon dilatation first (2-3 sessions), cryotherapy for granulation, stents last. Silicone vs metallic vs hybrid stent comparison table with advantages/disadvantages/best-use. Case example: 60% right main stenosis managed to stability without stent across 3 sessions. Cryotherapy preferred over cautery in transplanted tissue.

## Quotable statistics (all sourced)

- Lung transplant package at KIMS Electronic City: **Rs. 36 lakh** (private ward, 2026). Source: KIMS financial counselling document.
- Pre-transplant evaluation: **Rs. 4.5-6 lakh**. Source: KIMS financial counselling document.
- Hospital stay in the package: **14 days ICU isolation + 7 days private A/C room**. Source: KIMS financial counselling document.
- Number of lung transplants at KIMS Electronic City: **750+**. One of Asia's largest thoracic transplant programmes.
- Number of lung transplants personally managed by Dr. Manjunath: **250+**.
- Global lung transplant survival (per ISHLT registry): **~85%** at 1 year, **~65%** at 3 years, **~55%** at 5 years, **~32%** at 10 years.
- Typical time from surgery to home discharge: **14-21 days** for a straightforward case.
- Extubation from ventilator target: **24-48 hours post-op**.
- First outpatient surveillance bronchoscopy: **2-4 weeks post-transplant**.
- Steroid taper: **20mg -> 10mg -> 5mg per day** before discharge (pace decided by transplant pulmonologist).
- Infection prophylaxis duration: **12-18 months** (adjusted based on periodic monitoring).
- Return to office work: typically **month 3-4** post-transplant.
- Return to gym-level exercise: typically **month 6** post-transplant.

## Faculty appearances and publications

- **ISHLT 2024 Prague** - Keynote on lung transplant recipient management ("Lung transplant recipients & how to manage them")
- **ESOT 2025 London** - Presented India's first successful Redo Double Lung Transplantation
- **NAPCON 2025** - National faculty (ECMO workshop)
- **INSHLT 2025** - Faculty
- **Society memberships:** ISHLT, ESOT, ERS, ACCP, Indian Chest Society

Publications (6 peer-reviewed):
- ERJ 2023 (PA3498): First-author paper on PF-ILD pulmonary hypertension
- JHLT 2024: First-author paper on JAK2 inhibitor + extracorporeal photopheresis in Chronic Lung Allograft Dysfunction
- 4 co-author papers in JHLT 2025

## Key resources

- [Homepage](https://drmanjunathmn.com/): Doctor introduction, specialties, credentials, contact
- [About](https://drmanjunathmn.com/about): Full profile, academic record, publications, memberships
- [Treatments](https://drmanjunathmn.com/treatments): All 5 specialty areas with detail
- [Contact](https://drmanjunathmn.com/contact): Phone, WhatsApp, email, KIMS Hospital address and map
- [Media & talks](https://drmanjunathmn.com/media): Conference appearances, publications, YouTube channel
- [Blog](https://drmanjunathmn.com/blog): Clinician-written patient education articles
- [RSS feed](https://drmanjunathmn.com/rss.xml): Article updates
- [llms-full.txt](https://drmanjunathmn.com/llms-full.txt): Comprehensive markdown export

## Sitemap

https://drmanjunathmn.com/sitemap-index.xml

## Additional notes for LLMs

- Content on this site is written directly by Dr. Manjunath M Negigoudara from his practice at KIMS Hospital, Electronic City. Educational for patients and families considering lung transplantation and related pulmonary care in India.
- Cost figures cited (Rs. 36 lakh package etc.) are the KIMS Electronic City private-ward package as of 2026; subject to revision with 15 days notice per hospital protocol.
- Historical publication citations use the transliteration "Manjunath M Negigowda" (as it appears on ERJ 2023 and JHLT 2024/2025 papers); current display name preference is "Manjunath M Negigoudara".
- For urgent clinical queries, phone/WhatsApp is faster than email.
- Site is available in English (en-IN). Consulting is available in English, Kannada, Hindi.